The management of primary central nervous system (PCNSL) is one of the most
controversial topics in neuro-oncology because of the complexity of the disease and the …

Importance Primary central nervous system lymphoma (PCNSL) requires induction and
consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic …

Opinion statement Primary central nervous system lymphomas (PCNSLs) are very rare
neoplasms and continue to be challenging to treat. While high-dose methotrexate (HD-MTX) …

We analysed the therapeutic outcomes of all consecutive patients with primary central
nervous system lymphoma (PCNSL) registered in the prospective French database for …

Background High-dose chemotherapy (HDC) with autologous stem cell transplantation
(ASCT) has been investigated in patients with primary central nervous system lymphoma …

Simple Summary Most patients diagnosed with primary central nervous system lymphoma
(PCNSL) are 60 years or older and tend to have a poor prognosis. Evidence to guide and …

HD-MTX-based polychemotherapy remains the corner stone of the IT, but the best regimen
is not yet defined. Clinical trials assessing new IT regimens are ongoing. Intensive …

Simple Summary Primary central nervous system (CNS) lymphoma (PCNSL), arising and
remaining localized in the CNS, required the development of peculiar therapeutic strategies …

Opinion statement Primary central nervous system lymphoma is a complex disease with no
agreed-upon standard-of-care therapy. Induction therapy involves multiagent chemotherapy …

ABSTRACT A paucity of randomized phase III clinical trials in primary central nervous
system lymphoma (PCNSL) has resulted in no uniform consensus on the optimal strategy for …